Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils

Guillaume Monneret, Chantal Cossette, Sylvie Gravel, Joshua Rokach and William S. Powell
Journal of Pharmacology and Experimental Therapeutics January 2003, 304 (1) 349-355; DOI: https://doi.org/10.1124/jpet.102.042937
Guillaume Monneret
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Cossette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Gravel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Rokach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William S. Powell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Prostaglandin D2 (PGD2) is a mast cell-derived mediator that seems to play a role in asthma and allergic diseases. It is the only primary prostanoid to activate human eosinophils, which it accomplishes through the DP2receptor/chemoattractant receptor-homologous molecule expressed on T helper cell type 2 (Th2) cells (CRTH2). In addition, PGD2has both pro- and anti-inflammatory effects via the adenylyl cyclase-coupled DP1 receptor. To attempt to identify potent and selective DP2 receptor agonists we compared the abilities of a series of PGD2 analogs to activate eosinophils via the DP2 receptor with their abilities to stimulate adenylyl cyclase in platelets via the DP1receptor. All of the PGD2 analogs tested stimulated CD11b expression and actin polymerization with a rank order of potency of 15R-methyl-PGD2 > PGD2 > 17-phenyl-18,19,20-trinor-PGD2 > 15S-methyl-PGD2 ≈ 16,16-dimethyl-PGD2 > 11-keto-fluprostenol. Surprisingly, 15R-methyl-PGD2, which has the unnatural R -configuration at carbon 15, was about 5 times more potent than PGD2 and about 75 times more potent than 15S-methyl-PGD2. 15R-methyl-PGD2(EC50 value of 1.7 nM) was also much more potent as an eosinophil chemoattractant than PGD2(EC50 value of 10 nM) and 15S-methyl-PGD2(EC50 value of 128 nM). Cross-desensitization experiments indicated that 15R-methyl-PGD2 acts through the DP2 receptor. None of the PGD2 analogs tested elevated platelet cAMP by more than 20% of the maximal level in response to PGD2. However, in contrast to eosinophils, the most active was 15S-methyl-PGD2. In conclusion, 15R-methyl-PGD2 is the most potent known DP2 receptor agonist, and because of its selectivity and resistance to metabolism, should be a useful tool in probing the physiological role of this receptor in inflammatory diseases.

Footnotes

  • ↵1 Current address: Flow Cytometry Unit, Immunology Laboratory, Lyon-Sud University Hospital, 69495 Pierre-Bénite, France.

  • This study was supported by the Canadian Institutes of Health Research (Grant MOP-6254, to W.S.P.), the J. T. Costello Memorial Research Fund, and the National Institutes of Health (Grant DK44730, to J.R.). J.R. acknowledges the National Science Foundation for an AMX-360 NMR instrument (Grant CHE-90-13145).

  • DOI: 10.1124/jpet.102.042937

  • Abbreviations:
    PG
    prostaglandin
    Th2
    T helper cell type 2
    CRTH2
    chemoattractant receptor-homologous molecule expressed on Th2 cells
    PBS
    phosphate-buffered saline
    VLA-4
    very late antigen 4
    17-Ph-PGD2
    17-phenyl-18,19,20-trinor-PGD2
    LTB4
    leukotriene B4
    5-oxo-ETE
    5-oxo-6,8,11,14-eicosatetraenoic acid
    • Received August 8, 2002.
    • Accepted September 20, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 304 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 304, Issue 1
1 Jan 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils

Guillaume Monneret, Chantal Cossette, Sylvie Gravel, Joshua Rokach and William S. Powell
Journal of Pharmacology and Experimental Therapeutics January 1, 2003, 304 (1) 349-355; DOI: https://doi.org/10.1124/jpet.102.042937

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils

Guillaume Monneret, Chantal Cossette, Sylvie Gravel, Joshua Rokach and William S. Powell
Journal of Pharmacology and Experimental Therapeutics January 1, 2003, 304 (1) 349-355; DOI: https://doi.org/10.1124/jpet.102.042937
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lipopolysaccharide Induces Epithelium- and Prostaglandin E2-Dependent Relaxation of Mouse Isolated Trachea through Activation of Cyclooxygenase (COX)-1 and COX-2
  • Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship
  • Protease-Activated Receptor-2 Peptides Activate Neurokinin-1 Receptors in the Mouse Isolated Trachea
Show more INFLAMMATION AND IMMUNOPHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics